This brand new award recognises Cell Signaling Technology for its continued success in the Alzheimer's Disease field over the last three years.

Our judges made this award based on CiteAb data gathered over the last three years (2016 - 2018), highlighting Cell Signaling Technology as the company which has seen the largest increase in its share of citations for products used in Alzheimer’s research over this time.

Dr Andrew Chalmers, founder of CiteAb, said: “Congratulations to Cell Signaling Technology on winning our Antibody Supplier Succeeding in Alzheimer’s Research award. This is an increasingly important area of research, with the World Health Organisation claiming that the numbers of people living with the disease globally will increase from 50 million in 2018 to 152 million in 2050.

“By providing reliable, excellent quality products for research in this field, Cell Signaling Technology will play an important role in efforts to understand the causes, diagnosis, prevention, treatment and cure of Alzheimer’s.”